Ad
Thursday, 25 October 2018
Eisai, Biogen Alzheimer's data fails to convince skeptics
Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment